Gallbladder motility in systemic sclerosis

Lock, Guntram; Zeuner, M.; Kammerl, Martin C.; Läng, B; Schölmerich, Jürgen; Holstege, Axel

doi:10.1007/bf01816437

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding cholelithiasis, it was significantly lower in SSc patients compared to controls. Two studies in the literature showed that gallbladder motility in patients with SSc was not significantly reduced when compared to controls [ 21 , 22 ], consistent with our findings.…”

Section: Discussionsupporting

confidence: 92%

Gastrointestinal manifestations associated with systemic sclerosis: results from the nationwide inpatient sample

Alastal

Hammad

Renno

et al. 2017

aog

View full text Add to dashboard Cite

BackgroundSystemic sclerosis (SSc) is a multisystem disease associated with significant morbidity and increased mortality. The prevalence of different gastrointestinal (GI) manifestations has been investigated in multiple, but mainly small, retrospective studies. In this study, we investigated the prevalence and risk for a broad spectrum of GI disorders and malignancies in a large sample of inpatients with SSc in the United States.MethodsWe conducted a retrospective analysis using the 2010-2011 Healthcare Cost and Utilization Project – Nationwide Inpatient Sample (HCUP-NIS). SSc patients were identified by ICD-9-CM code 710.1. Non-SSc patients (“controls”) were matched to cases 4:1 by age and sex. We examined demographics, clinical characteristics, and a range of GI conditions.ResultsFrom 15,824,031 total patients, 13,633 cases of SSc were matched to 54,532 controls. The prevalence of GI manifestations among SSc patients was 59.24% compared to 29.96% for controls (P<0.0001). Significantly elevated GI manifestations in SSc patients included dysphagia (4.3% vs. 1.9%, P<0.0001), esophageal reflux (34.8% vs. 15.4%, P<0.0001), Barrett’s esophagus (1.7% vs. 0.3%, P<0.0001), constipation (6% vs. 4.6%, P<0.0001), diarrhea (4.5% vs. 2.4%, P<0.0001), fecal incontinence (0.4% vs. 0.2%, P<0.0001), and celiac disease (0.2% vs. 0%, P<0.0001). Some GI disorders were significantly lower in SSc patients, including cholelithiasis (1.6% vs. 2.1%, P<0.0001) and GI malignancies (1% vs. 2.2%, P<0.0001).ConclusionsOur results emphasize the established association between SSc and esophageal disorders, such as dysphagia and reflux disease. Our analysis indicated a significant positive association between SSc and celiac disease, and a negative association between SSC and cholelithiasis.

show abstract

Section: Discussionsupporting

confidence: 92%